Navigation Links
Gene Therapy Shows Promise for Parkinson's
Date:10/14/2009

e clinical trial in humans is in progress. "So far, six Parkinson's disease patients have been treated -- no serious adverse events, encouraging results so far," Jarraya said. "[But] the study is not ended, so still no final results."

Roughly 50,000 Americans are diagnosed with Parkinson's disease each year, according to the U.S. National Institute of Neurological Disorders and Stroke. The average age of onset is 60.

More information

The U.S. National Institute of Neurological Disorders and Stroke has more on Parkinson's disease.



SOURCES: Fatta Nahab, M.D., assistant professor, neurology, and director, movement disorder research, University of Miami Miller School Medicine, Miami; Bechir Jarraya, M.D., Ph.D., Department of Neurosurgery, Henri-Mondor Hospital, Paris, and head, cognitive and translation neuroscience laboratory, Inserm (National Institute of Health and Medical Research), Paris; Oct. 14, 2009, Science Translational Medicine Medicine


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Vision restoration therapy shown to improve brain activity in brain injured patients
2. HIV therapy in pregnancy-data support WHO recommendations
3. Family-based treatment more effective than supportive psychotherapy in treating bulimia
4. Trial to Test Gene Therapy for Angina in Women
5. One of the Largest Post-WHI Physician Surveys Shows More Education is Needed: Patient Misinformation About Hormone Therapy Remains High
6. Aromatherapy Gift Line Sheds Humorous Light on Modern Therapy
7. Chemotherapy may be culprit for fatigue in breast cancer survivors
8. Atlanta Falcons Physical Therapy Centers Set to Launch This Fall
9. New Drug No Substitute for Standard Blood-Clot Therapy
10. Stem Cell Therapy Disappoints Against Rare Kidney Ailment
11. Nucletron Announces Management Buy-Out to More Effectively Meet the Demands of Its Customers and the Radiation Therapy Community

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...Nov. 20 /PRNewswire-FirstCall/ - NUCRYST Pharmaceu...g of Shareholders will be held on Monday, December...er approval of two special resolutions. The first ... sale of all or substantially all of the assets of...in the asset purchase agreement dated November 10,...
(Date:11/20/2009)..., Nov. 20 Rates of infec...ked in late October, but the pandemic flu virus co... age groups, including the elderly, according to a...E: DGX ), the world,s leading provider of diagno...its most recent Quest Diagnostics Health Trends(TM...
(Date:11/20/2009)...0 The following is a st...e Nevada Health Care Association: ,, "The Nevad...ks Senate Majority Leader Harry Reid for his leade...r goal of protecting every Nevada seniors, ongoing...ng the strength and viability of our state,s vital...
(Date:11/20/2009)...ember 20, 2009Emergency medical service (EMS) prov...,000 cardiac arrests each year. Only 5 to 10 perc...ve. Better quality cardiopulmonary resuscitation ... associated with better patient outcome. The Resu... clinical research network to study prehospital tr...
(Date:11/20/2009)...igh and is expected to continue, CDC says, , ...reas of the United States are seeing declines in H...said Friday, and while the disease remains widespr...eported last week. , "We are beginning to see s...try, but there is still a lot of influenza everywh...
Breaking Medicine News(10 mins):Health News:NUCRYST Announces Special Meeting of Shareholders 2Health News:NUCRYST Announces Special Meeting of Shareholders 3Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 2Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 3Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 2Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 3Health News:Swine Flu Declining in Some Parts of U.S. 2Health News:Swine Flu Declining in Some Parts of U.S. 3
...C., Jan. 9 Palmetto GBA, a leading provider of te...l government, has been selected by the federal Cen... process and pay all fee-for-service Medicare clai...ded Palmetto GBA a contract with a base period of ...
...O, Mich., Jan. 9 Stryker Corporation,(NYSE: SYK...ion for the fourth,quarter of 2008, representing a...r the fourth quarter of 2007, and were $6,718 mill...onstant currency basis,net sales increased 7.7% fo...
...OGA, Tenn., Jan. 9 Shared Health, one of the,nati...hanges, announced today,the appointment of Adnane ...formation officer. , Khalil will focus on buil...re than 15 years experience in creating, integrati...
...es & Martinis at Dashing Diva , , NEW YORK, J...a baby now, but they should be seeking the answers...,ll be able to have a baby when they are ready. Th...ght to do everything possible to keep from getting...
... Biocoat, Inc., Horsham, PA announced... been created and linked to the company,s website ...turers and designers can go to find the latest dev...9 -- Biocoat, Inc., Horsham, PA announced that a ...
...n. 8 New York City Mayor Michael R. Bloomberg dec...and presented a proclamation to Ilchi Lee, preside...tion) and developer of Brain Education, a revoluti...ng the power of individuals to change themselves a...
Other Medicine News:Health News:CMS Selects Palmetto GBA to Administer Medicare Program in Four States 2Health News:Stryker Updates Expected 2008 Results and Provides 2009 Outlook 2Health News:Stryker Updates Expected 2008 Results and Provides 2009 Outlook 3Health News:Stryker Updates Expected 2008 Results and Provides 2009 Outlook 4Health News:Shared Health(R) Names Adnane Khalil as Chief Information Officer 2Health News:Free Early Education Program to Lower Infertility Rates 2Health News:Free Early Education Program to Lower Infertility Rates 3Health News:Blog Launched to Discuss Developments in Hydrophilic Coatings for Medical Devices 2Health News:NYC Mayor Michael R. Bloomberg Declares January 8th 'IBREA Brain Education Day' 2
(Date:11/20/2009)..., , CARY, N.C., Nov. 20 /PRNewswire-FirstC...TX ), a specialty pharmaceutical company focused o...icant products primarily for the respiratory and r...d a Warning Letter from the Food and Drug Administ...ble tablets (Phenylephrine HCl 10 mg, Pyrilamine M...
(Date:11/20/2009)..., , GLENWOOD, Ill., Nov. 20 /PRNewswire-Fir...se financial results for the fiscal fourth quarter...mber 1, 2009. ,, The company will host a confer...09, at 2:00 p.m. Eastern Time. Investors may acces...e United States and Canada), or 480-629-9835 (inte...
(Date:11/20/2009)..., , HARRISBURG, Pa., Nov. 20 /PRNewswire-...n providing free H1N1 flu shots to members of prio...he vaccine. ,, A total of 18 clinics are being ...s are from 2 p.m. to 8 p.m. Hours on Saturday, Nov... the clinics will operate from 2 p.m. to 8 p.m. ,...
Breaking Medicine Technology:Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal 2Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal 3Landauer, Inc. Sets Date and Time for Announcement of Fiscal Fourth Quarter and Full Year 2009 Results 2Pennsylvania Department of Health Begins Statewide H1N1 Vaccination Clinics Targeting Priority Populations; Some Appointments Still Available 2HHS Awards MedImmune Contract to Manufacture Live Attenuated Nasal Spray Vaccine for Novel Influenza A 28H1N1 29 12381 1HHS Awards MedImmune Contract to Manufacture Live Attenuated Nasal Spray Vaccine for Novel Influenza A 28H1N1 29 12381 2HHS Awards MedImmune Contract to Manufacture Live Attenuated Nasal Spray Vaccine for Novel Influenza A 28H1N1 29 12381 3HHS Awards MedImmune Contract to Manufacture Live Attenuated Nasal Spray Vaccine for Novel Influenza A 28H1N1 29 12381 4Keryx Biopharmaceuticals Announces Positive Data from a Randomized Multi Center Placebo Controlled Phase 2 Combination Study of KRX 0401 28Perifos 4500 1Keryx Biopharmaceuticals Announces Positive Data from a Randomized Multi Center Placebo Controlled Phase 2 Combination Study of KRX 0401 28Perifos 4500 2Keryx Biopharmaceuticals Announces Positive Data from a Randomized Multi Center Placebo Controlled Phase 2 Combination Study of KRX 0401 28Perifos 4500 3Keryx Biopharmaceuticals Announces Positive Data from a Randomized Multi Center Placebo Controlled Phase 2 Combination Study of KRX 0401 28Perifos 4500 4Keryx Biopharmaceuticals Announces Positive Data from a Randomized Multi Center Placebo Controlled Phase 2 Combination Study of KRX 0401 28Perifos 4500 5Keryx Biopharmaceuticals Announces Positive Data from a Randomized Multi Center Placebo Controlled Phase 2 Combination Study of KRX 0401 28Perifos 4500 6MDS Nordion Urges Government of Canada to Complete MAPLE Project to Address Current Medical Isotope Supply Shortage 47449 1MDS Nordion Urges Government of Canada to Complete MAPLE Project to Address Current Medical Isotope Supply Shortage 47449 2MDS Nordion Urges Government of Canada to Complete MAPLE Project to Address Current Medical Isotope Supply Shortage 47449 3MDS Nordion Urges Government of Canada to Complete MAPLE Project to Address Current Medical Isotope Supply Shortage 47449 4MDS Nordion Urges Government of Canada to Complete MAPLE Project to Address Current Medical Isotope Supply Shortage 47449 5
...be Assured of No Banned Substances, BASKING RIDGE...wholly-owned subsidiary of Millennium Biotechnolog...ced today that Surgex(TM), (http://www.surgexsport...ned,Substance Control Group,s (BSCG) certification...n the US that uses a World Anti Doping Agency,accr...
...uate Anti-Tumor Activity of Bavituximab in ...N, Calif., Jan. 29 Peregrine,Pharmaceuticals, Inc...ical,company developing targeted therapies for the...on (HCV), today announced that patient screening,h...the safety and efficacy,of bavituximab in combinat...
Other Medicine Technology:Surgex(TM) Becomes the First and Only BSCG (Banned Substance Control Group) Certified Product Which is Clinically Proven Effective in Sports Recovery and Performance 2Surgex(TM) Becomes the First and Only BSCG (Banned Substance Control Group) Certified Product Which is Clinically Proven Effective in Sports Recovery and Performance 3Surgex(TM) Becomes the First and Only BSCG (Banned Substance Control Group) Certified Product Which is Clinically Proven Effective in Sports Recovery and Performance 4Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer 2Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer 3Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer 4
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
Medicine Products: